P122: Small Molecules as Chemical and Pharmacological Tools for Neuroinflammatory Diseases Treatment (with Emphasis on Multiple Sclerosis)
Authors
Abstract:
Multiple Sclerosis (MS) is a neuroinflammatory disease resulting in degeneration of the myelin sheaths and death of oligodendrocytes. So far, several strategies have been introduced to control the disease. Treatment with small molecules is one of the strategies that have recently attracted the attention in the scientific community. These molecules that target epigenetic and other cellular processes offer powerful tools for disease treatment from several ways including modification of cell function by inhibition/activation of specific proteins and also reprogramming somatic cells and manipulating their fate to a desired cell type. This process ultimately leads to demyelination cessation and remyelination stimulation. Studies show that specific small molecules such as Src family kinase inhibitor PP2, and Chir99021 chemically have been effective in modulating disease progression and also its treatment. There are several studies that have reported successful efforts of using these molecules for MS control and treatment. In this article the authors will review recent studies that have been published in this research area. We have searched the PubMed databases comprehensively and accurately to find peer reviewed articles with Small molecule and multiple sclerosis keywords. We studied them carefully and selected the most prestigious and the most recent of them to ensure that all knowledge on this topic is discussed. Also we put meeting abstracts under precise consideration to ensure that all references have been investigated. In this review we emphasized on the great opportunity of using small molecules for MS control and treatment. There are several studies that have used small molecules to inhibit demyelination and induce remyelination that indicates the growing attention to this research area. Nevertheless, there are several challenges in using these cells for treating MS but we hope that efforts of this growing research community will completely solve all the problems and someday this therapeutic approach will take a great step in neuroinflammatory disease treatment.
similar resources
P 53: Stem Cell Therapy for Treatment of Autoimmune Diseases (with Emphasis on Multiple Sclerosis)
Autoimmune diseases have been described as an interesting and poorly understood group of disorders. There are many challenges in the respective scientific societies concerning the nature, causes and the therapeutic approaches of these diseases. In accordance with the evidences the nature and etiology of these disorders is multifactorial and complex but the clearest definition could be expressed...
full textPromoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis
Multiple Sclerosis (MS) is a neurodegenerative disease where immune-driven demyelination occurs with inefficient remyelination, but therapies are limited, especially those to enhance repair. Here, we show that the dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, VP3.15, a heterocyclic small molecule with good pharmacokinetic properties and safety profile, improves in vi...
full textp 53: stem cell therapy for treatment of autoimmune diseases (with emphasis on multiple sclerosis)
autoimmune diseases have been described as an interesting and poorly understood group of disorders. there are many challenges in the respective scientific societies concerning the nature, causes and the therapeutic approaches of these diseases. in accordance with the evidences the nature and etiology of these disorders is multifactorial and complex but the clearest definition could be expressed...
full textThe Effects of Combined Treadmill Training and Pharmacological Treatment on Management of Multiple Sclerosis Female Patients
Objectives: To compare the effectiveness of two treatment methods of ‘combination pharmacological treatment and treadmill training’ and ‘pharmacological treatment’ on management of multiple sclerosis (MS) female patients. Methods: In this quasi experimental and interventional study a sample of 20 MS patients (mean age: 36.75 years) with Expanded Disability Status Scal...
full textUtilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases
Several drugs have been approved for treatment of multiple sclerosis (MS). Dimethyl fumarate (DMF) is utilized as an oral drug to treat this disease and is proven to be potent with less side effects than several other drugs. On the other hand, monomethyl fumarate (MMF), a related compound, has not been examined in greater details although it has the potential as a therapeutic drug for MS and ot...
full textPharmacological treatment of pain in multiple sclerosis.
Pain is a common symptom in multiple sclerosis (MS) and was recently estimated to be experienced by up to 75% of patients. Nociceptive and neuropathic pain in MS may be present concurrently and at different stages of the disease and may be associated with other symptoms. Evidence for treating pain in MS is limited. Many clinical features of pain are often unrecognized by clinicians and are diff...
full textMy Resources
Journal title
volume 6 issue 2
pages 153- 153
publication date 2018-04
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023